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BY-NC-ND license (http://creativecomAbstract Angiogenesis is an important factor in the development and progression of pros-
tate cancer (PCA). We aimed to investigate the values of vascular-endothelial-growth-
factor (VEGF) expression level and microvessel density (MVD) in the prediction of PCA diag-
nosis at repeated prostate biopsy (re-PBx). We retrospectively evaluated 167 patients with
re-PBx according to elevated prostate-specific antigen levels, suspicious digital rectal exam-
ination, and the presence of premalignant lesions. Patients with PCA on re-PBx were included
in the cancer group (nZ 17). Patients with benign prostatic hyperplasia or normal tissues on
re-PBx were included in the control group (n Z 21). The groups were compared according to
the expression level of VEGF and MVD in initial prostate biopsy. There was no statistically sig-
nificant difference between groups according to age and serum prostate-specific-antigen
values. The mean VEGF scores of the cancer and control groups were 232.64  11.14 and
183.09  14.56, respectively (p < 0.05). The mean MVD of the biopsy samples in the cancer
and control groups were 246.47  17.59 n/mm2 and 197.33  16.26 n/mm2, respectively
(p < 0.05). The cutoff values of VEGF scores and MVD were set as 200 and 215, respectively,
for PCA detection in our study. Our results showed that the expression level of VEGF and MVD
significantly increased in the initial prostate-biopsy samples of patients with PCA diagnosed
with re-PBx. The evaluation of VEGF expression level and MVD might have an important value
in the prediction of PCA at re-PBx. The expression level of VEGF and MVD should be kept ineclare no conflicts of interest.
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prostatic tissue.
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Prostate cancer (PCA) accounts for 10% of all cancers in
men, and causes 9% of cancer-specific deaths in men in
developed countries [1]. The incidence of PCA has
increased with the development of new diagnostic tools.
The measurement of prostate-specific antigen (PSA) and its
derivatives, the increased frequency of prostate biopsy
(PBx), and the specific diagnosis of premalignancy by biopsy
in pathological investigations are the main factors resulting
in repeat PBx (re-PBx). Histopathological signs on first PBx
and PSA levels at follow-up are mainly used for the pre-
diction of PCA diagnosis on re-PBx [2].
Angiogenesis is an important factor in the development
and progression of PCA and other tumors. PCA cells secrete
proangiogenic factors, such as vascular endothelial growth
factor (VEGF), basic fibroblast growth factor, interleukin-8,
and platelet-derived growth factor [3].
Microvessel density (MVD) is the quantitative indicator of
tumoral angiogenesis. Endothelium-specific antibodies,
such as CD24, CD31, CD34, CD105, and von Willebrand
factor (factor VIII), are used for the immunohistochemical
staining of vessels, and MVD is calculated by counting the
small and meandering vessels of the tumor. Recent in-
vestigations have suggested that increased MVD is related
to high histological grade and poor prognosis in breast,
lung, colon, stomach, malign melanoma, prostate, and
bladder cancer [4,5].
Differences in VEGF expression level and MVD between
PCA, premalignant lesions, and benign prostatic hyperpla-
sia (BPH) have been reported. A pathological investigation
of radical-prostatectomy materials showed an increased
VEGF expression and MVD in PCA tissue in comparison to
benign prostatic glands [6e8].
Here, we compared the VEGF expression level and MVD
at re-PBx between patients initially diagnosed with BPH and
PCA. We also investigated the values of VEGF expression
level and MVD in the prediction of PCA diagnosis at re-PBx.Methods
We retrospectively evaluated 1055 patients who underwent
transrectal ultrasound (TRUS)-guided PBx between January
2000 and June 2013 at our department. A total of 167 pa-
tients underwent re-PBx during the study period due to an
increased PSA level, suspicious digital rectal examination
(DRE), or premalignant lesions, such as atypical small acinar
proliferation (ASAP) and high-grade prostatic intraepithelial
neoplasm (HGPIN). A total of 129 patients with ASAP,
HGPIN, or prostatic inflammation were excluded. The
remaining 38 patients were evaluated according to age,family history of PCA, laboratory findings, serum total PSA
values, physical-examination findings, DRE findings, and
radiological findings. The interval between the initial PBx
and re-PBx was 6e12 months.
The patients were divided into the cancer and control
groups. All patients in both groups were diagnosed with BPH
on initial PBx. Seventeen patients with a PCA diagnosis at
rebiopsy were included in the cancer group. The remaining
21 patients with a BPH diagnosis at re-PBx were included in
the control group. These groups were compared according
to VEGF score and MVD at initial PBx.
This study was approved by the Baskent University
Institutional Review Board (project number KA 13/41), and
was supported by the Baskent University Research Fund.
Technique of TRUS-guided PBx
All patients were orally administered 500-mg ciprofloxacin
twice daily for 2 days before undergoing PBx. The patient
was placed in the left lateral decubitus position under local
anesthesia for all TRUS evaluations and PBx procedures. A
Logiq C2 ultrasound device with a transrectal probe (GE
Healthcare, Milwaukee, WI, USA) was used to evaluate the
prostate, and 5 mL of 2% prilocaine (2.5 mL for each side)
was used as the local anesthetic agent and was injected
bilaterally with a 22-gauge, 20-cm Chiba aspiration biopsy
needle (GEOTEK Medical Corporation, Ankara, Turkey) just
lateral to the junction between the prostate base and the
seminal vesicle for periprostatic nerve blockade. The pros-
tate was morphologically examined in transverse and
sagittal planes after prilocaine infiltration. The ellipsoid
formula was used to calculate the prostate volume. Five
minutes after prilocaine injection, the PBx was performed in
a transverse plane using the 10- to 12-core technique with a
biopsy gun containing an 18-gauge, 25-cm Maxicore auto-
matic biopsy gun needle (GEOTEK Medical Corporation).
Immunohistochemical staining and evaluation of
VEGF expression and MVD levels
For all groups, hematoxylin/eosin-stained slides were
reevaluated before immunohistochemical staining by the
same pathologist. One core-biopsy sample of approximately
2 cm in diameter from each patient was used for immu-
nohistochemical staining. Four-micrometer-wide paraffin
blocks in polylysine-coated lam were deparaffinized in
xylene and dehydrated in a series of baths containing
decreasing concentrations of ethanol; then, the blocks
were stained using the streptavidinebiotineperoxidase
method. Briefly, the sections were heated in citrate buffer
(10mM, pH 6.0) at 120C for 20e255 minutes (pressure
cooker) for antigen retrieval, and were rinsed three times
Figure 1. Distribution of vascular-endothelial-growth-factor
scores in the control and cancer groups. The difference was
significant between both groups (* p Z 0.013). Data were
expressed as mean  standard deviation. VEGF Z vascular
endothelial growth factor.
76 E. Kervancioglu et al.in deionized distilled water. Endogenous peroxidase activ-
ity was blocked by 30 minutes of incubation with 0.3%
hydrogen peroxidase. The sections were then incubated
with the primary antibodies VEGF antibody (BioGenex,
Fremont, CA, USA; immunogen: human recombinant
VEGF165; clone: polyclonal; 1/100) and CD34 antibody
(Thermo Scientific, Fremont, CA, USA; immunogen:
detergent-solubilized vesicular suspension prepared from a
perfusate of human term placenta; clone: QBend/10; 1/
100) for 24 hours at room temperature. Then, the sections
were stained according to the streptavidinebiotin method.
The immunoreaction was visualized with 3-30-dia-
minobenzidine/aminoethylcarbazole (Thermo Scientific
Dako, Glostrup, Denmark) as a chromogen. The slides were
counterstained with Mayer’s hematoxylin solution and were
mounted. All stages of staining were carried out at room
temperature to avoid drying.
VEGF positivity was mostly detected in the epithelial
cells of the prostate. Only 5% of the total VEGF staining was
observed in fibroblasts. Therefore, we evaluated the VEGF
expression according to epithelial staining. Cytoplasmic/
membranous staining was considered positive for VEGF. The
staining intensity was graded as grade 0 (absence of stain-
ing), grade 1 (mild staining), grade 2 (moderate staining),
and grade 3 (severe staining). The VEGF score was calcu-
lated by multiplying the percent of stained epithelial cells
in the biopsy sample with the grade of the VEGF staining.
The VEGF score was used to make comparisons between the
two groups.
All vessels in the biopsy samples with positive CD34
staining were counted. The vessels that had a lumen size
large enough to contain eight erythrocytes were excluded.
The vessels were evaluated under 40 magnification.
For MVD scoring, the most vascularized regions were
selected at low magnification, and the microvessels were
counted in three nonoverlapping areas at high-power
magnification (400). The mean value of the three MVD
counts was considered the main score for MVD for each
case. MVD is presented as the number of vessels/mm2 (n/
mm2) for each group.
Statistical analysis
The data are expressed as the mean  standard deviation.
The demographic parameters, MVD values, and VEGF scores
were compared between the two groups. SPSS 16.0 for
Windows (SPSS Inc., Chicago, IL, USA) was used for the
statistical analyses. The contributions of the parameters
were evaluated by the Levene test, and then the inde-
pendent t test was used to compare the data between the
two groups. Differences with a p < 0.05 were considered
statistically significant.
Results
The mean ages of the cancer and control groups were
72.5  7.5 years and 70.2  6.6 years, respectively, and this
difference was not statistically significant (pZ 0.324). The
mean blood-serum total PSA levels of the cancer and con-
trol groups were 11.46  7.68 ng/mL and 10.81  9.2 ng/
mL, respectively, and that difference was also notstatistically significant (p Z 0.258). The Gleason scores of
the patients in the cancer group were 6 in 13 (76.47%) pa-
tients, 7 in two (11.76%) patients, and 9 in one (5.88%)
patient. Microscopically detectable cancer was found in
only one (5.88%) patient in the cancer group.
VEGF
The mean percentages of VEGF staining in prostatic
epithelial cells in the cancer and control groups were
92.35  6.87% and 82.85  21.18%, respectively, and the
mean VEGF scores of the cancer and control groups were
232.64  11.14 and 183.09  14.56, respectively. The VEGF
scores of the two groups were significantly different
(p Z 0.013) and are presented in Figure 1. The grade of
VEGF staining of epithelial cells in the cancer group was
higher than that in the control group, and these data are
presented in Figures 2A and 2B. The cutoff value for the
VEGF score was set at 200 for all patients, and had sensi-
tivity, specificity, and positive and negative predictive
values for PCA of 70.58%, 61.9%, 60%, and 72.2%, respec-
tively. The area under the receiver-operating-character-
istic curve was 0.71.
MVD
MVD was determined by counting the CD34-stained vessels
of the biopsy samples, and the mean MVD values in the
cancer and control groups were 246.47  17.59 n/mm2 and
197.33  16.26 n/mm2, respectively. The difference in MVD
between the two groups was statistically significant
(pZ 0.048). The MVD values for both groups are presented
in Figure 3. For both groups, areas with increased MVD are
shown in Figures 4A and 4B. According to these results, the
MVD values were higher in the cancer group than in the
control group. The cutoff value for MVD was set at 215 for
all patients, and had sensitivity, specificity, and positive
and negative predictive values for PCA of 70.58%, 61.9%,
60%, and 72.2%, respectively. The area under the receiver-
operating-characteristic curve was 0.718.
Figure 2. The vascular-endothelial-growth-factor expression
in the epithelium of prostatic glands. (hematoxylin/eosin,
40). (A) Low expression of vascular endothelial growth factor
in the control group; (B) high expression of vascular endothelial
growth factor in the cancer group.
Figure 4. Microvessel density in prostatic tissue, determined
by CD34 immunohistochemical staining. (A) Low density of
microvessels in the control group (CD34, 40); (B) high density
of microvessels in the cancer group (CD34, 40).
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The main factors for the prediction of PCA at re-PBx are the
pathological findings of ASAP and HGPIN at initial PBx, and
PSA elevation at the time of re-PBx [2]. Angiogenesis is
important for the metastasis and growth of cancer. VEGF is
a growth factor that stimulates angiogenesis, which con-
tributes to tumor growth [9,10]. The quantitative marker ofFigure 3. Distribution of microvessel density (CD34þ) in the
control and cancer groups. The difference was significant be-
tween both groups (** p Z 0.048). Data were expressed as
mean  standard deviation. MVD Z microvessel density.angiogenesis is MVD. For some tumors, a relationship be-
tween high MVD and poor prognosis has been reported
[4,5]. Varying levels of MVD and VEGF expression in benign
tissues and inflammatory tissues have also been shown by
several studies [6e8]. We aimed to compare the VEGF
scores and MVD values at initial PBx of patients diagnosed
with BPH and PCA at re-PBx. We also aimed to investigate
the values of VEGF level and MVD at initial PBx for the
prediction of PCA.
Re-PBx is a required procedure in the presence of PCA
suspicion. The main factors that influence the decision to
perform re-PBx are the patient’s symptoms, an elevated
serum PSA level, signs suspicious of PCA on DRE, and pre-
malignant lesions at initial PBx. Keetch et al. [11] reported
a PCA risk of 25% in males with PSA levels of 4e20 ng/mL.
The PCA detection rate of re-PBx is 20% in patients with a
BPH diagnosis at initial PBx [11]. Djavan et al. [12] reported
that two consecutive PBx procedures were effective to
detect most clinically significant PCA cases among patients
with PSA levels of 4e10 ng/mL. They suggested that a third
and fourth PBx should only be applied for selected patients
[12]. The reported cancer-detection rate of repeat TRUS-
guided PBx for patients with HGPIN at initial PBx was 23%
[13]. In contrast, for patients with ASAP at initial PBx, the
PCA-detection rate of re-PBx was approximately 40e50%.
The PCA region of the prostate in these patients has been
reported to be similar to the ASAP region identified by
78 E. Kervancioglu et al.initial PBx [14,15]. Patients with ASAP and HGPIN at initial
PBx were excluded from our study. Only patients with BPH
or normal prostatic tissue at initial PBx were selected to
investigate the importance of VEGF level and MVD in the
prediction of PCA independent from ASAP and HGPIN.
Although the appropriate interval between two consec-
utive PBx procedures is controversial, the PCA incidence
increases as that interval is increased [15]. The interval
between the initial and re-PBx was 6e12 months in our
study, and corresponded to the timing of the follow-up
measurements of PSA level. Most patients in our study un-
derwent repeat TRUS-guided PBx due to an elevated PSA
level on consecutive measurements.
Understanding the molecular alterations in the early
period of PCA is important. Angiogenesis is a critical stage
of carcinogenesis. Angiogenesis is the main factor influ-
encing the development and progression of PCA, and is
related to a high Gleason score, metastasis, and poor
prognosis [3]. The most important factor of angiogenesis is
VEGF. Metastasis and mortality in PCA were reported to be
related to VEGF expression [16]. The blood-plasma VEGF
level was reported to be higher in patients with PCA and to
serve as an independent prognostic factor for metastasis in
men [17,18]. A study that independently investigated the
pathological samples of 55 patients with radical prosta-
tectomy showed that VEGF expression and MVD were
significantly higher in the PCA region than the BPH, HGPIN,
and normal prostatic-tissue regions in the same sample.
Additionally, VEGF expression and MVD were reported to be
higher in the BPH region than in the HGPIN region. The
authors of that study suggested the existence of an upward
trend in angiogenesis from BPH to premalignant to PCA
tissues [6]. A similar study reported that MVD and VEGF
expression were significantly higher in PCA than in benign
tissues according to radical-prostatectomy pathology find-
ings [7]. On the other hand, Wu et al. [8] did not find a
significant difference in the expression of VEGF between
tissues with benign prostatic epithelial cells and malignant
tissues in patients who had undergone radical prostatec-
tomy. In another study, the pathological samples of 72
patients who underwent transurethral resection of the
prostate, radical prostatectomy, and TRUS-guided PBx were
examined to determine the progression of PCA. Higher MVD
values were reported in PCA patients with disease of higher
clinic stage, and VEGF immunoreactivity was more intense
in PCA regions than in benign tissues in the same samples
[19]. The topography of neovascularization in PCA was
evaluated in samples obtained from 14 patients who had
undergone radical prostatectomy. Regions of BPH and PCA
in the same samples were compared, and the MVD values of
benign tissues were increased near to malignant tissue at
radical prostatectomy [20]. Our hypothesis is supported by
these studies. Our study is the first in the literature to
compare the initial PBx pathologies of patients diagnosed
with BPH and PCA by re-PBx. We investigated the probable
roles of MVD and VEGF score in the prediction of PCA in-
dependent of ASAP and HGPIN, as the prognostic roles of
these parameters are controversial. We found that the
VEGF score and MVD at initial PBx were higher in patients
diagnosed with PCA than in patients diagnosed with BPH at
re-PBx. When the cutoff values of VEGF score and MVD were
set at 200 and 215 for all patients, their sensitivity andspecificity values for PCA detection were 70.58% and 61.9%,
respectively. However, we believe that higher sensitivity
and specificity values will be found by future investigations
with larger sample sizes. Our findings showed that VEGF
expression and MVD may be important markers for deter-
mining whether to perform re-PBx.
Lekas et al. [21] compared the MVD values of tissues in
patients diagnosed with BPH and PCA after surgery. The
immunoreactivity of CD34 in the hyperplasic glands of the
prostate near the PCA was higher than that in other tissues.
However, VEGF expression was not compared between BPH
and benign tissues near the PCA in this study. The expres-
sion of VEGF was reported to be significantly increased in
PCA tissues in comparison to BPH tissues [21]. We evaluated
the initial PBx samples of patients diagnosed with BPH and
PCA at re-PBx. We hypothesized that the initial PBx tissues
of the cancer group were adjacent to the undiagnosed
malignant tissue. Because of this hypothesis, we felt that
our experimental design was valid for investigating the
predictive roles of VEGF and MVD for PCA.
Angiogenesis is also related to inflammation in the
prostate. MVD and VEGF expression have been shown to be
affected by prostatic infections. The expressions of VEGF,
cyclooxygenase-2, and B cell lymphoma 2 and MVD were
studied in pathological samples of patients with PCA and
BPH. Patients with BPH were divided into two groups: in-
flammatory BPH group and noninflammatory BPH group.
The expression of VEGF in tissues in the inflammatory BPH
group was higher than that in tissues of the noninflamma-
tory BPH group and was lower than that in patients with
PCA [22]. Patients with prostatic inflammation were
excluded from our study to avoid the effect of inflammation
on VEGF expression and MVD.
A limitation of our study was the small number of
included patients. However, our patients were selected
from a large series of patients who underwent PBx. Another
limitation of this study was its retrospective nature.
We found that the angiogenetic factors VEGF score and
MVD were increased at initial PBx in patients who were
later diagnosed with PCA. The sensitivity and specificity
values of VEGF score and MVD for the prediction of PCA
were 70.58% and 61.9%, respectively. Our results suggest
that VEGF expression and MVD might be important factors
in deciding whether to perform re-PBx. Our study may lead
to investigations of the carcinogenic parameters that have
roles in the early period of PCA. There is no doubt that the
findings of this study should be supported by the results of
prospective randomized studies with a larger series of
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